Patents Assigned to State University
-
Publication number: 20100152819Abstract: Methods for enhancing blood and lymph flow in the extremities of a human subject are disclosed. In one aspect, the methods rely on a stimulus effective to displace the skin of a plantar or palmer surface of the subject, thereby enhancing blood and lymph flow in the extremity associated with the stimulated plantar or palmer surface. In another aspect, the methods rely on an electrical stimulus to directly stimulate cutaneous receptors in a plantar or palmer surface of the subject, thereby enhancing blood and lymph flow in the extremity associated with the stimulated cutaneous receptors. Apparatus for enhancing blood and lymph flow in the extremities of a human subject according to the methods of the present invention are also disclosed.Type: ApplicationFiled: October 1, 2009Publication date: June 17, 2010Applicant: Research Foundation of State University of New YorkInventor: Kenneth J. MCLEOD
-
Publication number: 20100152699Abstract: A nanochannel delivery device and method of manufacturing and use. The nanochannel delivery device comprises an inlet, an outlet, and a nanochannel. The nanochannel may be oriented parallel to the primary plane of the nanochannel delivery device. The inlet and outlet may be in direct fluid communication with the nanochannel.Type: ApplicationFiled: November 13, 2009Publication date: June 17, 2010Applicants: The Board of Regents of the University of Texas System, The Ohio State University Research FoundationInventors: Mauro Ferrari, Xuewu Liu, Alessandro Grattoni, Daniel Fine, Randy Goodall, Sharath Hosali, Ryan Medema, Lee Hudson
-
Patent number: 7739091Abstract: The present invention is directed to a method of predicting the binding affinity between a first molecular entity and a second molecular entity. The method includes (1) calculating the free energy of binding ?Gbind between the first molecular entity and the second molecular entity according to the equation (17): ?Gbind=?0.82?X+/?+0.064?Xc/s?0.6Xsb?0.93Xhb?0.0007Xgap?0.06?Xtor?0.36??(17) where X+/? is the total number of exposed charged groups; Xc/s is the total number of exposed hydrophobic groups; Xsb is the total number of salt bridges; Xhb is the total number of hydrogen bonds; Xgap is the gap volume at the interface of the first molecular entity and the second molecular entity; Xtor is the total number of exposed side chain torsions; and where ? refers to the difference between the bound and unbound states; and (2) evaluating the free energy of binding to predict the binding affinity between the first and second molecular entities.Type: GrantFiled: March 21, 2007Date of Patent: June 15, 2010Assignee: The Research Foundation of State University of New YorkInventor: Joseph Audie
-
Patent number: 7737433Abstract: The electronic properties of molecular junctions of the general type carbon/molecule/TiO2/Au as examples of “molecular heterojunctions” consisting of a molecular monolayer and a semiconducting oxide. Junctions containing fluorene bonded to pyrolyzed photoresist film (PPF) were compared to those containing Al2O3 instead of fluorene, and those with only the TiO2 layer. The responses to voltage sweep and pulse stimulation were strongly dependent on junction composition and temperature. A transient current response lasting a few milliseconds results from injection and trapping of electrons in the TiO2 layer, and occurred in all three junction types studied. Conduction in PPF/TiO2/Au junctions is consistent with space charge limited conduction at low voltage, then a sharp increase in current once the space charge fills all the traps. With fluorene present, there is a slower, persistent change in junction conductance which may be removed by a reverse polarity pulse.Type: GrantFiled: September 28, 2006Date of Patent: June 15, 2010Assignees: The Ohio State University Research Foundation, Zettacore, Inc.Inventors: Richard L. McCreery, Kenneth J. Mobley, Jing Wu
-
Patent number: 7737123Abstract: Daunorubicin (“DNR”) compounds synthesized with uncommon sugars exhibit enhanced effectiveness in treating various drug-resistant cancers.Type: GrantFiled: May 12, 2006Date of Patent: June 15, 2010Assignee: The Ohio State University Research FoundationInventors: Guisheng Zhang, Lanyan Fang, Peng George Wang, Duxin Sun
-
Patent number: 7736892Abstract: Stem cells from human sources can have a variety of useful applications in disease treatment and biotechnology. More particularly the umbilical cord matrix cell cultures of the invention have a variety of totipotent, pluripotent, or multipotent cells for a variety of end uses from a non-controversial, universally available, species-specific source. The technology can have application to any amniotic animal, including agricultural and laboratory animals and humans. The invention relates to isolating the stem cells, culturing the stem cells, maintaining the stem cells, transforming the stem cells into useful cell types using genetic or other transformation technologies, stem cell and tissue banking and using untransformed or transformed cells in disease treatment.Type: GrantFiled: August 25, 2003Date of Patent: June 15, 2010Assignee: Kansas State University Research FoundationInventors: Mark L. Weiss, Deryl L. Troyer, Duane Davis, Kathy E. Mitchell
-
Patent number: 7737121Abstract: A method for stimulating insulin secretion by anthocyanidins and anthocyanins is described. The secretion can be in vivo in mammals, including humans, or in vitro.Type: GrantFiled: March 4, 2005Date of Patent: June 15, 2010Assignee: Board of Trustees of Michigan State UniversityInventors: Muraleedharan G. Nair, Bolleddula Jayaprakasam, L. Karl Olson, Shaiju K. Vareed
-
Publication number: 20100143677Abstract: Methods to control and prevent polymer films from buckling are provided. Buckled morphologies are created by thermally cycling or mechanically compressing a substrate such as poly(dimethylsiloxane) (PDMS) coated with a polyelectrolyte multilayer film. By varying the dimensions of the surface topography relative to the buckling wavelength (e.g., pattern size is less than, equal to, and greater than the buckling wavelength) the orientation and the local morphology of the buckled films is controlled. Based on the information obtained, we demonstrate how to alleviate the unavoidable buckling by incorporating nanoparticles into the film. In addition, we studied the effect of the silica layer that results from oxygen plasma treatment and the critical temperature for permanent film buckling.Type: ApplicationFiled: November 15, 2007Publication date: June 10, 2010Applicant: Board of Trustees of Michigan State UniversityInventors: Ilsoon Lee, Troy R. Hendricks
-
Publication number: 20100140154Abstract: The present invention discloses methods of preparing a continuous, porous metal oxide monolith in a container. The method involves providing a reaction mixture containing a metal salt or metal alkoxide compound, a solvent, and a porogenic reagent. Next, an epoxide is added to the reaction mixture under conditions effective to initiate condensation and polymerization of the reaction mixture. Then, a container is filled with the reaction mixture after epoxide addition to obtain a continuous, porous metal oxide monolith in the container. The present invention also discloses columns including a tubular container and a continuous, porous Group IV metal oxide monolith in contact with the inner walls of the tubular container, where the Group IV metal oxide monolith is free of any support or matrix material, and other articles including a continuous, porous Group IV metal oxide monolith, where the metal oxide monolith is free of any support or matrix material.Type: ApplicationFiled: March 9, 2005Publication date: June 10, 2010Applicant: The Research Foundation of State University of New YorkInventors: Luis A. Colon, David C. Hoth
-
Publication number: 20100143822Abstract: A membrane electrode assembly (MEA) for a fuel cell comprising a catalyst layer and a method of making the same. The catalyst layer can include a plurality of catalyst nanoparticles, e.g., platinum, disposed on buckypaper. The catalyst layer can have 1% or less binder prior to attachment to the membrane electrode assembly. The catalyst layer can include (a) single-wall nanotubes, small diameter multi-wall nanotubes, or both, and (b) large diameter multi-wall nanotubes, carbon nanofibers, or both. The ratio of (a) to (b) can range from 1:2 to 1:20. The catalyst layer can produce a surface area utilization efficiency of at least 60% and the platinum utilization efficiency can be 0.50 gPt/kW or less.Type: ApplicationFiled: July 17, 2009Publication date: June 10, 2010Applicant: Florida State University Research FoundationInventors: Jian-ping Zheng, Zhiyong Liang, Ben Wang, Chun Zhang, Wei Zhu
-
Publication number: 20100146667Abstract: Disclosed are specific mutants of L3 and transgenic plants that produce them. The plants exhibit increased resistance to fungal toxins that target ribosomal L3 protein. Also disclosed are transgenic plants that co-produce L3 mutant and an RIP protein, and exhibit increased resistance to various fungal toxins and viruses, while reducing toxicity normally associated with production of the RIP. Uses of the L3 mutants in animals are further disclosed.Type: ApplicationFiled: March 30, 2009Publication date: June 10, 2010Applicant: Rutgers, The State UniversityInventors: Nilgun E. Tumer, Rong Di
-
Publication number: 20100145003Abstract: Catalytic processes for preparing caprolactam, pipecolinic acid, and their derivatives, from lysine or alpha-amino-epsilon-caprolactam starting materials, and products produced thereby. A process for preparing caprolactam or a derivative thereof, the process comprising contacting a reactant comprising lysine or alpha aminocaprolactam with a catalyst and a gas comprising hydrogen gas, in the presence of a solvent. The catalyst may be provided on a support material, such as a transition metal.Type: ApplicationFiled: February 20, 2008Publication date: June 10, 2010Applicant: BOARD of Trustees of Michigan State UniversityInventor: John W. Frost
-
Publication number: 20100146642Abstract: The invention relates to compositions comprising, and methods utilizing PBK1 protein and DNA, including a method of detecting type 1 diabetes; a mammalian pancreas-derived cell comprising a recombinant nucleic acid encoding a PBK1 protein; a method of identifying a PBK1 modulator; a pharmaceutical composition for treatment of type 2 diabetes in a subject; a method of screening for an agent that treats a metabolic disease; delivery of PBK-1 DNA to a subject to stimulate pancreatic beta cell differentiation and/or regeneration; a method for stimulating cell differentiation and/or regeneration in a pancreatic beta cell; usage of transgenic mice with targeted deletion or overexpression of the PBK-1 gene to test efficacy and specificity of PBK-1 modulator compounds.Type: ApplicationFiled: May 22, 2008Publication date: June 10, 2010Applicant: The Pennsylvania State UniversityInventors: Yuguang Shi, Guangming Ye
-
Publication number: 20100146653Abstract: Particular aspects provide novel recombinant cells and cell lines (e.g., macrophage cell lines) that are permissive for propagation of porcine reproductive and respiratory syndrome virus (PRRSV) propagation in vitro or in vivo. In certain aspects, novel nucleic acid sequences encoding porcine sialoadhesin were transfected into existing macrophage cell-lines from other species, rendering them permissive to PRRSV infection, and suitable for propagation of PRRSV. Particular aspects provide exemplary recombinant cloned cell lines that support the replication of PRRSV, with an obtainable PRRSV titre of between 2×105/ml and 2×106/ml. Additional aspects provide novel nucleic acid sequences and polymorphisms thereof that encode for porcine sialoadhesin. Further aspects provide PRRSV propagation and preparation methods using the novel recombinant cell lines, and methods for PRRSV antigen and vaccine production using same.Type: ApplicationFiled: February 13, 2008Publication date: June 10, 2010Applicant: Washington State University Research FoundationInventors: Subramaniam Srikumaran, Weiguo Liu, Sudarvili Shanthalingam
-
Patent number: 7732436Abstract: The synthesis and biological activity of indoloazepines and acid amine salts thereof which are structurally related to naturally-occurring hymenialdisine is disclosed. Naturally-occurring hymenialdisine obtained from the sponge is a potent inhibitor of production of cytokines interleukin-2 (IL-2) and tumor necrosis factor-? (TNF-?). The chemically-synthesized indoloazepines of the invention also inhibit production of IL-2 and TNF-?. The indoloazepines are useful for treating inflammatory diseases, particularly diseases associated with kinases NF-?B or GSK-3? activation or NF-?B activated gene expression products. The indoloazepines are useful for the treatment of cancer by the inhibition of kinases CHK1 and CHK2.Type: GrantFiled: August 9, 2006Date of Patent: June 8, 2010Assignee: Board Of Trustees Of Michigan State UniversityInventor: Jetze J. Tepe
-
Patent number: 7731578Abstract: A harvesting machine includes a self-propelled vehicle adapted for separating grain from non-grain material, a cleaning shoe and a fan for controlling air flow. The fan is positioned downstream of the cleaning shoe and the fan having an air inlet for providing air to the fan and an aspiration outlet for providing air from the fan. The fan assists in reducing static air pressure within the harvesting machine. The fan may be a centrifugal fan. The harvesting machine may further include a chopper operatively connected to the vehicle and adapted for receiving the non-grain material and chopping the non-grain material and a blower adapted for assisting in conveying the non-grain material from the chopper such as for collection in a collection container.Type: GrantFiled: October 31, 2008Date of Patent: June 8, 2010Assignee: Iowa State University Research Foundation, Inc.Inventors: Stuart J. Birrell, Mark D. Dilts, Benjamin J. Schlesser
-
Patent number: 7733961Abstract: A method of enhancing a resolution of an image by fusing images includes applying a principal component analysis to a multispectral image to obtain a plurality of principal components, and replacing a first component in the plurality of principal components by a panchromatic image. The method further includes resampling remaining principal components to a resolution of the panchromatic image, and applying an inverse principal analysis to the panchromatic image and the remaining principal components to obtain a fused image of the panchromatic image and the multispectral image.Type: GrantFiled: April 17, 2006Date of Patent: June 8, 2010Assignee: Mississippi State University Research and Technology CorporationInventors: Charles G. O'Hara, Anil Cheriyadat, Suyoung Seo, Bijay Shrestha, Veeraraghavan Vijayaraj, Nicolas H. Younan
-
Patent number: 7734859Abstract: A hardware/software system and method that collectively enables virtualization of the host computer's native I/O system architecture via the Internet and LANs. The invention includes a solution to the problems of the relatively narrow focus of iSCSI, the direct connect limitation of PCI Express, and the inaccessibility of PCI Express for expansion in blade architectures.Type: GrantFiled: April 21, 2008Date of Patent: June 8, 2010Assignees: Nuon, Inc, Arizona Board of Regents for and on behalf of Arizona State UniversityInventors: David A. Daniel, Joseph Hui
-
Patent number: 7731979Abstract: The unnatural amino acid analogue 2-fluorohistidine (2-FHis) was incorporated into protective antigen to produce a protein which resists protonation at physiological pH by reducing the side-chain pKa. The protein structure was unperturbed by the incorporation of fluorinated histidine residues, and the heptameric (2-FHisPA63)7 could form ion conducting channels, and bind to the PA-binding domain of LF (LFN), but translocation of LFN in planar lipid bilayers was blocked. Further, while (2-FHisPA63)7 could bind to host cells and in vitro to the host cellular receptor, pore formation in the presence of the receptor was blocked, and LFN-DTA mediated cytotoxicity in CHO-K1 cells was blocked. The modified PA is useful as both a vaccine and an antitoxin, providing epitopes for the production of antibodies against PA, but preventing key steps in pathogenesis (pore formation, translocation).Type: GrantFiled: November 13, 2007Date of Patent: June 8, 2010Assignee: Wichita State UniversityInventor: James G. Bann
-
Patent number: PP21066Abstract: A male asparagus (Asparagus officinalis) hybrid denoted ‘NJ977’. The plant has many desirable traits including vigorous plant growth, high yield, good resistance to rust (Puccinia asparagi) and good field tolerance to asparagus root and crown rot caused by Fusarium oxysporum and Fusarium moniliforme. These desirable traits have been shown to be transmissible to its progenies. The invention relates to plants and plant parts of ‘NJ977’ plant. The invention further relates to hybrid asparagus seeds and plants produced by crossing the male asparagus ‘NJ977’ plant with any female asparagus plant.Type: GrantFiled: March 4, 2008Date of Patent: June 15, 2010Assignee: Rutgers, The State UniversityInventors: Chee-kok Chin, Stephen A. Garrison, John J. Kinelski